This study is currently not recruiting participants.

Phase 1b/2 Multicenter Open-label Study of Carfilzomib Carboplatin and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for subjects with Extensive-Stage Small-Cell Lung Cancer (ES SCLC).

Description

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for subjects with Extensive-Stage Small-Cell Lung Cancer (ES SCLC).

Details
Condition Lung Cancer
Age 18years - 100years
Clinical Study IdentifierTX3903
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.